Human leukocyte antigen-specific antibodies and gamma-interferon stimulate human microvascular and glomerular endothelial cells to produce complement factor C4

Transplantation

Volumn 93, Issue 9, 2012, Pages 867-873

  Hamer, Rizwan ^a,b   Molostvov, Guerman ^b   Lowe, David ^c   Satchell, Simon ^d   Mathieson, Peter ^d   Ilyas, Rebecca ^b   Mitchell, Daniel A ^b   Lam, For T ^a   Kashi, Habib ^a   Tan, Lam Chin ^a   Imray, Chris ^a   Fletcher, Simon ^a   Briggs, David ^c   Krishnan, Nithya ^a   Higgins, Robert ^a   Zehnder, Daniel ^a,b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Antibody mediated rejection; Complement; Endothelial cells

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; GAMMA INTERFERON; HLA ANTIBODY; SMALL INTERFERING RNA;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CELL DIFFERENTIATION; CELL STIMULATION; CONTROLLED STUDY; CYTOPLASM; ENDOTHELIUM CELL; GLOMERULAR ENDOTHELIAL CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROVASCULAR ENDOTHELIAL CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; WESTERN BLOTTING;

ANTIBODIES; ANTIVIRAL AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; COMPLEMENT C4; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLOMERULAR MESANGIUM; GRAFT REJECTION; HLA ANTIGENS; HUMANS; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION;

EID: 84860773873     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824b3762     Document Type: Article

References (38)

1. Patel R, Terasaki P. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
2. Terasaki PI. Humoral theory of transplantation. Am J Transplant 2003; 3: 665.
3. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 1464.
4. Feucht H, Felber E, Gokel M, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86: 464.
5. Feucht H, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333.
6. Halloran P, Schlaut J, Solez K, et al. The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550.
7. Colvin R. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
8. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807.
9. Camous L, Roumenina L, Bigot S, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 2011; 117: 1340.
10. Pratt J, Basheer S, Sacks S. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582.
11. Zhou W, Marsh J, Sacks S. Intrarenal synthesis of complement. Kidney Int 2001; 59: 1227.
12. Tang S, Zhou W, Sheerin N, et al. Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 1999; 162: 4336.
13. Farrar C, Zhou W, Lin T, et al. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006; 20: 217.
14. Satchell S, Anderson K, Mathieson P. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 2004; 15: 566.
15. Higgins R, Lowe D, Hathaway M, et al. Double filtration plasmapheresis in antibody-incompatible kidney transplantation. Ther Apher Dial 2010; 14: 392.
16. Higgins R, David L, Mark H, et al. HLA antibody incompatible renal transplantation: Excellent medium term outcomes with cytotoxic negative crossmatch. Transplantation 2011; 92: 900.
17. Naughton M, Botto M, Carter M, et al. Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. J Immunol 1996; 156: 3051.
18. Zhou W, Medof M, Heeger P, et al. Graft-derived complement as a mediator of transplant injury. Curr Opin Immunol 2007; 19: 569.
19. Peng Q, Li K, Patel H, et al. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006; 176: 3330.
20. Woltman A, de Fijter J, Zuidwijk K, et al. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int 2007; 71: 1001.
21. Thurman J, Lucia M, Ljubanovic D, et al. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005; 67: 524.
22. Lin T, Zhou W, Farrar C, et al. Deficiency of C4 from donor or recipient mouse fails to prevent renal allograft rejection. Am J Pathol 2006; 168: 1241.
23. Bao L, Wang Y, Chang A, et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol 2007; 18: 811.
24. Klegeris A, Bissonnette C, Dorovini-Zis K, et al. Expression of complement messenger RNAs by human endothelial cells. Brain Res 2000; 871: 1.
25. Satchell S, Tasman C, Singh A, et al. Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int 2006; 69: 1633.
26. Walport M. Complement. First of two parts. N Engl J Med 2001; 344: 1058.
27. Walport M. Complement. Second of two parts. N Engl J Med 2001; 344: 1140.
28. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527.
29. Shcheglovitova O, Antonov A, Kabaeva N, et al. EInterferon production by primary culture of human endothelial cells. Biull Eksp Biol Med 1989; 108: 580.
30. Einhorn S, Eldor A, Vlodavsky I, et al. Production and characterization of interferon from endothelial cells. J Cell Physiol 1985; 122: 200.
31. Bergamaschini L, Gobbo G, Gatti S, et al. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin Exp Immunol 2001; 126: 412.
32. Kroshus T, Salerno C, Yeh C, et al. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation. Transplantation 2000; 69: 2282.
33. Patel H, Smith R, Sacks S, et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 2006; 17: 1102.
34. Tillou X, Poirier N, Le Bas-Bernardet S, et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010; 78: 152.
35. Dawson JE, Candal FJ, George VG, et al. Human endothelial cells as an alternative to DH82 cells for isolation of Ehrlichia chaffeensis, E canis, and Rickettsia rickettsii. Pathobiology 1993; 61: 293.
36. Ades E, Candal F, Swerlick R, et al. HMEC-1: Establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683.
37. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46: 355.
38. Procter J, Crawford J, Bunce M, et al. A rapid molecular method (polymerase chain reaction with sequence-specific primers) to genotype for ABO blood group and secretor status and its potential for organ transplants. Tissue Antigens 1997; 50: 475.